AstraZeneca completes transfer of global rights to Eklira & Duaklir to Covis Pharma
Summary : AstraZeneca has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and…
Summary : AstraZeneca has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and…
Summary : Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with AstraZeneca…
Summary – French health authorities have approved the use of an antibody treatment made by AstraZeneca for high-risk people who show resistance…
Synopsis – England’s National Institute for Health and Care Excellence (NICE) has given a thumbs up to Sobi’s paroxysmal nocturnal hemoglobinuria (PNH)…
Summary : With the FDA’s emergency use authorization today of AstraZeneca’s long-acting antibody cocktail, the roughly 2% of U.S. residents who are…
Summary : The company also said studies are underway to provide information on the impact of the new Omicron variant on Evusheld,…
SYNOPSIS: GlaxoSmithKline Plc released positive trial results for a potential blockbuster anemia pill the company is hoping will bolster its pharma portfolio…
KEYPOINTS AstraZeneca has agreed to transfer its global rights to Eklira (Aclidinium bromide), known as Tudorza in the US, and Duaklir (Aclidinium…
Key Points – AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges,…